JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gao, Z.
Right arrow Articles by Belardinelli, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gao, Z.
Right arrow Articles by Belardinelli, L.

Vol. 298, Issue 1, 209-218, July 2001

Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists

Zhenhai Gao1 , Zhihe Li1 , Stephen P. Baker, Robert D. Lasley, Stephanie Meyer, Elfatih Elzein, Venkata Palle, Jeff A. Zablocki, Brent Blackburn and Luiz Belardinelli

Departments of Pharmacological Sciences (Z.G., Z.L., S.M., B.B., L.B.) and Bioorganic Chemistry (E.E., V.P., J.A.Z., B.B.), CV Therapeutics, Palo Alto, California; Department of Pharmacology, University of Florida, Gainesville, Florida (S.P.B.); and Department of Surgery, University of Kentucky, Lexington, Kentucky (R.D.L.)

Several potent and selective A2A adenosine receptor agonists are currently available. These compounds have a high affinity for the A2A receptor and a long duration of action. However, in situations where a short duration of action is desired, currently available A2A receptor agonists are less than ideal. From a series of recently synthesized A2A receptor agonists, two agonists (CVT-3146 and CVT-3033) with low affinity were selected for further characterization as selective and short-acting coronary vasodilators. Both compounds were selective for the A2A adenosine receptor (AdoR) versus the A1, A2B, and A3AdoR in binding and functional studies. CVT-3146 and CVT-3033 appeared to be weak partial agonists to cause cAMP accumulation in PC12 cells, but were full and potent agonists to cause coronary vasodilation, a response that has a very large A2A receptor reserve. However, the durations of action of CVT-3146 and CVT-3033 were remarkably shorter than those of the high-affinity agonists CGS21680 or WRC0470, presumably due to the relative lower affinity of CVT-3146 and CVT-3033 for the A2A receptor. Indeed, an inverse relationship was found between the affinity of the various agonists for the A2A receptor and the duration of their actions. These data indicate that low-affinity agonists can produce a response that is of equivalent magnitude but more rapid in termination than that caused by a high-affinity agonist. Hence, the low-affinity A2A agonists CVT-3146 and CVT-3033 may prove to be superior to currently available high-affinity agonists as coronary vasodilators during myocardial imaging with radionuclide agents.

1 These authors contributed equally to this work.

0022-3565/01/2981-0209$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
A. K. Dhalla, M.-Y. Wong, W.-Q. Wang, I. Biaggioni, and L. Belardinelli
Tachycardia Caused by A2A Adenosine Receptor Agonists Is Mediated by Direct Sympathoexcitation in Awake Rats
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 695 - 702.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. C. Hendel, T. M. Bateman, M. D. Cerqueira, A. E. Iskandrian, J. A. Leppo, B. Blackburn, and J. J. Mahmarian
Initial Clinical Experience With Regadenoson, a Novel Selective A2A Agonist for Pharmacologic Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging
J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2069 - 2075.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Zhao, A. Linke, X. Xu, M. Ochoa, F. Belloni, L. Belardinelli, and T. H. Hintze
Comparative Profile of Vasodilation by CVT-3146, a Novel A2A Receptor Agonist, and Adenosine in Conscious Dogs
J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 182 - 189.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
K. Murphy, V. Gerzanich, H. Zhou, S. Ivanova, Y. Dong, G. Hoffman, G. A. West, H. R. Winn, and J. M. Simard
Adenosine-A2a Receptor Down-Regulates Cerebral Smooth Muscle L-Type Ca2+ Channel Activity via Protein Tyrosine Phosphatase, Not cAMP-Dependent Protein Kinase
Mol. Pharmacol., September 1, 2003; 64(3): 640 - 649.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Panther, S. Corinti, M. Idzko, Y. Herouy, M. Napp, A. la Sala, G. Girolomoni, and J. Norgauer
Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells
Blood, May 15, 2003; 101(10): 3985 - 3990.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. L. Kilpatrick, P. Narayan, R. M. Mentzer Jr., and R. D. Lasley
Cardiac myocyte adenosine A2a receptor activation fails to alter cAMP or contractility: role of receptor localization
Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H1035 - H1040.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.